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Abstract
Osteoarthritis (OA) of the joint is a prevalent disease accompanied by chronic, debilitating pain. Recent clinical evidence has
demonstrated that central sensitization contributes to OA pain. An improved understanding of how OA joint pathology
impacts upon the central processing of pain is crucial for the identification of novel analgesic targets/new therapeutic
strategies.
Inhibitory cannabinoid 2 (CB2) receptors attenuate peripheral immune cell function and modulate central neuro-immune
responses in models of neurodegeneration. Systemic administration of the CB2 receptor agonist JWH133 attenuated OA-
induced pain behaviour, and the changes in circulating pro- and anti-inflammatory cytokines exhibited in this model.
Electrophysiological studies revealed that spinal administration of JWH133 inhibited noxious-evoked responses of spinal
neurones in the model of OA pain, but not in control rats, indicating a novel spinal role of this target. We further
demonstrate dynamic changes in spinal CB2 receptor mRNA and protein expression in an OA pain model. The expression of
CB2 receptor protein by both neurones and microglia in the spinal cord was significantly increased in the model of OA.
Hallmarks of central sensitization, significant spinal astrogliosis and increases in activity of metalloproteases MMP-2 and
MMP-9 in the spinal cord were evident in the model of OA pain. Systemic administration of JWH133 attenuated these
markers of central sensitization, providing a neurobiological basis for analgesic effects of the CB2 receptor in this model of
OA pain. Analysis of human spinal cord revealed a negative correlation between spinal cord CB2 receptor mRNA and
macroscopic knee chondropathy.
These data provide new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated
combined with converging pre-clinical evidence that activation of CB2 receptors inhibits central sensitization and its
contribution to the manifestation of chronic OA pain. These findings suggest that targeting CB2 receptors may have
therapeutic potential for treating OA pain.
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Introduction
Osteoarthritis (OA) is one of the most common causes of
chronic pain with individuals experiencing pain at rest, on weight
bearing [1], and pain from sites distal to the joint [2,3]. The spread
of pain to areas away from the diseased joint [2] suggests that
changes in the central processing of sensory inputs contribute to
OA pain. Indeed a recent study provided psychophysical and
imaging evidence supporting a contribution of central sensitization
to OA pain [4]. Central sensitization plays a pivotal role in the
switch from acute to chronic pain mechanisms [5,6] and the
manifestation of altered sensory responses, such as touch-evoked
pain (mechanical allodynia), in models of chronic pain [7]. Spinal
neuronal facilitation and the activation of spinal microglia and
astrocytes [8,9,10] play fundamental roles in these processes.
Experimental models of OA, such as the intra-articular injection of
monosodium acetate (MIA), are associated with joint pathology
[11,12] and pain behaviour [13,14,15,16,17] comparable to
clinical OA. We have demonstrated the facilitation of spinal
neuronal responses [17], and the activation of spinal microglia and
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astrocytes [18,19,20,21] has also been demonstrated, in the MIA
model of OA pain. These observations support the use of this
model of OA pain to study the neurobiological mechanisms
underpinning the manifestation of central sensitization associated
with OA.
Current analgesic treatments for OA pain have either incom-
plete efficacy, or potentially severe adverse events [22], limiting
treatment options for OA sufferers. The discovery of a contribu-
tion of central sensitization to OA pain supports the investigation
of novel drug targets within the central nervous system for the
treatment of OA pain. The analgesic effects produced by
activation of the cannabinoid (CB) receptor system are well
documented and mediated by multiple sites of action [23].
Dynamic changes in the spinal endocannabinoid system are
evident in the MIA model of OA pain; endocannabinoid levels are
elevated in the spinal cord and tonically regulate neuronal activity
via CB1 and CB2 receptors [17]. Over-expression of CB2 receptors
significantly attenuated mechanical allodynia in a mouse model of
OA pain, without influencing joint pathology, suggesting that CB2
receptors can regulate OA pain responses via sites distinct from the
joint [24]. It is well accepted that activation of spinal CB2
receptors attenuates pain behaviour in models of neuropathic pain
[25,26], via modulation of microglia and astrocytic pro- and anti-
inflammatory responses [27,28]. We hypothesised that activation
of CB2 receptors would attenuate OA pain responses in a model of
OA pain, and that these effects would be associated with a
decrease in systemic and spinal markers of central sensitization.
The aim of this study was to determine whether activation of the
CB2 receptor attenuates pain behaviour in the MIA model of OA
pain, and then to investigate the sites of action, and mechanisms
by which, analgesic effects were produced. The contribution of a
spinal site of action was evaluated by electrophysiological
recordings of spinal neurones, quantification of spinal CB2
receptor gene expression and immunohistochemical quantification
of the cellular location of CB2 receptors in the spinal cord in MIA-
treated rats, compared to controls. The influence of the CB2
receptor agonist JWH133 on spinal markers of central sensitiza-
tion was determined, providing a mechanistic basis for the
analgesic effects of this intervention in this model. The final series
of experiments determined whether spinal CB2 receptor expres-
sion is correlated with knee joint damage (macroscopic chondro-
pathy score) in human post mortem samples.
Methods
Studies were in accordance with UK Home Office Animals
(Scientific Procedures) Act (1986) and the International Associa-
tion for the Study of Pain guidelines and were approved by ethical
review board at the University of Nottingham. Data are presented
in line with the ARRIVE guidelines. Male Sprague Dawley rats
(arrival weight of 130–150 g, Charles River U.K.) were used. CB2
homozygous knockout mice (CB2 KO, 005786, B6.129P2-
Cnr2tm1Dgen/J, n = 9) and wild type mice (000664, C57BL/J6,
n = 5) were provided by Professor Lichtman (File S1). All animal
studies were conducted in a manner that minimised animal
distress, and euthanization of the animal occurred via an
appropriate S1 technique (as listed by the UK Home Office), or
by terminal overdose with sodium pentobarbital followed by
transcardial perfusion (once animals were areflexic).
MIA model induction
Adult male Sprague Dawley rats (180–200 g at time of
induction) were anesthetised with isoflurane (2.5–3%) in 100%
oxygen (1 L per min) and received a single intra-articular injection
of monosodium iodoacetate (MIA; 1 mg/50 ml; Sigma U.K.) in
saline through the infra-patellar ligament of the left knee [17].
Control rats received intra-articular injection of 50 ml of saline.
Pain behaviour was quantified as a change in hindlimb weight-
distribution (Incapacitance Tester, Linton Instrumentation, U.K.)
and hindpaw mechanical withdrawal thresholds (von Frey testing),
as previously described [17].
Systemic drug administration and pain behaviour
MIA-treated rats received daily subcutaneous injection of either
JWH133 (a CB2 receptor agonist with a Ki of 3.4 nm and
approximately 200 fold selectivity for CB2 over CB1 receptors
[29]) at a dose of 1 mg/kg at a volume of 1 ml/kg (n= 8), or
vehicle, 5% ethanol. 5% emulphor and 90% saline (n = 8) from
day 0–28 post-MIA injection. Changes in hind limb weight-
distribution and hindpaw mechanical withdrawal thresholds were
measured in a blinded fashion.
ELISA assays
Microwell strips for Interleukin-1 beta (IL-1b), tumor necrosis
factor-alpha (TNF-a), and Interleukin 10 (IL-10) were washed with
wash buffer. Standard curve solution was added to standard curve
wells, 50 ml of sample serum + 50 ml sample diluent and 50 ml of
biotin conjugate were mixed together (mixture A) and added to the
wells and incubated for 2 hours at room temperature with gentle
agitation. Mixture A was removed and wells washed and 100 ml of
diluted Streptavidin-HRP (mixture B) was added and incubated
for 1 hour at room temperature with gentle agitation. Mixture B
was removed and wells washed and 100 ml of TMB substrate
solution was added to the wells and incubated for 20 min at room
temperature with gentle agitation until the highest standard curve
point had developed (dark blue colour). Enzymatic reaction was
stopped by the addition of 100 ml of stop solution. Plates were read
on a spectrophotometer using 405 nm reference wavelength, and
cytokine concentration determined from the standard curve. All
samples and standards were run in triplicate.
In vivo electrophysiology
Rats were anaesthetised, placed in a stereotaxic frame and a
laminectomy (L4-5) was performed [17]. Extracellular single-unit
recordings of deep wide dynamic range dorsal horn neurones were
made, action potentials were digitised and quantified with a CED
micro1401 interface and Spike 2 software (Cambridge Electronic
Design, UK). Von Frey monofilaments (bending forces 10, 15, 26
and 60 g) were applied to the plantar surface of the neuronal
receptive field for 10 seconds and mean frequency of firing
recorded.
Effects of a spinal administration of the CB2 receptor selective
agonist [29] JWH-133 (8-486 ng/50 ml based on [25] n = 6
neurones in 6 rats for each group) or vehicle (0.0005–0.03%
EtOH in distilled water; n = 7 neurones in 7 MIA-treated rats and
n=9 neurones in 9 saline-treated rats, respectively) on mechan-
ically-evoked responses of dorsal horn neurones were studied.
Dorsal horn neurones were located between 700–900 mm from the
surface of the spinal cord and were located in laminae V–VI.
RNA extraction and cDNA synthesis
50 mg of frozen rat spinal cord tissue was homogenized in 2 ml
of ice cold Tri reagent (Sigma-Aldrich, UK) and RNA purified as
previously described [30]. mRNA was isolated from total RNA
using Dynabeads mRNA purification kits (Life Technologies). For
cDNA synthesis, mRNA was reverse transcribed using Superscript
III reverse transcriptase (Life Technologies). RNA was extracted
Cannabinoid CB2 Receptors and Osteoarthritis Pain
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from human spinal cord lumbar segment L4 (that had been
collected 24–48 hours post mortem and quick frozen in melting
isopentane) using a Pure LinkTM FFPE RNA Isolation Kit (Life
Technologies). 200 ng of total RNA was then reverse transcribed
as above.
Taqman quantitative real time polymerase chain reaction
Gene expression was quantified by Taqman quantitative real
time PCR using the relative standard curve method [31]. Beta-
actin was used as an invariant reference gene for normalization of
expression between samples. Primers and probes were designed
using Primer Express3 software (Applied Biosystems, UK), and
synthesised by MWG Biotech (Germany), see File S1. CB2
receptor gene expression was measured in ipsilateral and
contralateral rat lumbar (L3–L5) spinal cord. Gene expression
levels of CB1, CB2, GFAP and TRPV1 receptor and the enzyme
COX2 were quantified in human lumbar (L3–L5) spinal cord
tissue (see File S1).
Immunohistochemistry
Rats were overdosed with sodium pentobarbital and transcar-
dially perfused with saline and 4% paraformaldehyde (Sigma,
U.K). The lumbar spinal cord was removed, post-fixed and stored
in 30% sucrose. Immunohistochemistry (following citrate buffer
antigen retrieval) for spinal cord sections (40 mm) used goat anti
Iba-1 (1:500, Abcam, Cambridge, UK), rabbit anti-CB2 (ab3561
1:300, Abcam, Cambridge, UK), mouse anti-GFAP (1:100, Fisher
scientific UK), mouse anti-Neu-N (1:100, Anti-NeuN, clone A60
Millipore, Germany) antibodies. Secondary antibodies were
Alexafluor 568 conjugated Donkey anti-goat (1:200), Alexafluor
568 conjugated Donkey anti-mouse secondary antibody and
Alexafluor 488 conjugated Donkey anti-rabbit (1:200) (Molecular
probes, Oregon). Images were captured and processed identically
and any contrast enhancement applied consistently for each
image, as described in [19]. All images were digitally captured with
an 8 bit camera, thus giving grey level (intensity) values of 0–255.
NIR660-Mbc94 CB2 receptor probe assay
The details of the synthesis of the CB2 receptor probe
NIR6660-Mbc84 are included in File S1. Lumbar spinal cord
sections (10 mm) on silane-prepared slides (Sigma Aldrich) were
incubated in buffer A (50 mM Tris–HCl, 3 mM MgCl2, 0.2 mM
EGTA, 100 mM NaCl) for 1 hour, and then buffer A+0.5% BSA
(Buffer B) for 1 hour. Sections were incubated for 3 hours with
either ethanol (0.1%), JWH133 (3 mM) or SR144528 (1 mM) made
up in buffer B. Sections were incubated for 5 hours with NIR660-
Mbc94 (3 mM) alone or in the presence of JWH133 (3 mM) or
SR144528 (1 mM) in buffer B. Sections were washed, dried and
mounted in Polyvinyl alcohol mounting medium with NPG,
antifading (Sigma catalogue number: 10979). NIR660-Mbc94
staining was visualised and analysed using a Leica DMIRE2
fluorescence microscope, and Volocity 5.5 (PerkinElmer). A
300 ms image capture was used to ensure acquisition was in the
linear dynamic range of the camera. Details of the Cresyl violet,
Hoechst 33342, NIR660-Mbc94 staining protocol and Confocal
Microscopy image acquisition are in File S1.
Gelatin zymography
Rat spinal cords were homogenized in lysis buffer (50 mM Tris-
HCl,, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.1%
deoxycholic acid, 2 mg/ml leupeptin, 2 mg/ml aprotinin, and
1 mM PMSF PH. 7.4) and mixed for 3 h at 4uC. The
homogenate was centrifuged at 15,0006g for 15 min at 4uC.
Supernatant layer was removed and 20–30 mg of supernatant was
diluted in Zymogram Sample Buffer (Bio-Rad Laboratories, Inc,
161–0764) and loaded onto precast Zymogram gels (10%, gelatin,
10-well, 30 ml, 8.666.8 cm (W6L), Bio-Rad Laboratories, Inc,
161–1113). Electrophoresis was performed in Tris-glycine buffer
at 120–130 volts for 3 h. Gels were incubated for 3 hr at room
temperature in 100 ml of 3% Triton X-100 on a rotary shaker and
then with 200 ml of development buffer (Bio-Rad Laboratories,
Inc 161–0766) for a further 1 hour, gels were then incubated in
fresh development buffer at 37uC for 24–30 hr on a rotary shaker.
Bands were visualised by Coomassie Blue staining. Purified MMP-
9 and MMP-2 (5427-MM-010 and 924-MP-010, respectively, R &
D systems) were used as positive controls. Images of gel
zymograms were captured using a Li-CorH ODYSSEY imaging
system, using the gel scan function (linear manual setting of 6,
contrast 50/100 and brightness 50/100). For densitometry
analysis, we used IMAGE J (NIH open software with Macbio-
photonics plugins) software.
Chondropathy scoring of clinical samples
Post-mortem knee joints were obtained from recently deceased
patients. The presence and nature of knee pain in these cases is not
known. The articular cartilage integrity of the medial and lateral
femoral condyles and tibial plateaux of the knee joints were
determined by a single assessor as previously described [32,33].
Chondropathy was graded 0 (normal) to 4 (subchondral bone
exposure) and chondropathy scores were calculated as previously
described [32,33]. Total scores ranged from 0 to 400 for the joint,
and left and right knee scores were summed.
Statistical analysis
All statistics were calculated using Prism 5.0 software (Graph-
pad, La Jolla, USA). Data were analysed with either a one way or
two way ANOVA, a t-test, or Spearman correlation (*p,0.05,
**p,0.01, ***p,0.001). For data that did not pass normality
testing non-parametric statistics were used. Analysis of ELISA data
(TNFa and IL-1b) used a one sample t-test using detection limit of
kit as hypothetical value as there was no variation in saline +
vehicle group and MIA + JWH133 group, for IL-10 data a one-
way ANOVA was used. Correlations between human gene
expression and chondropathy or age were determined with either
a Pearson correlation or Spearman correlation depending on
whether data passed normality testing.
Results
CB2 receptor activation attenuates OA pain behaviour
and spinal neuronal responses
The ability of a selective CB2 agonist JWH133 to modulate OA
pain behaviour and noxious-evoked responses of spinal neurones
was investigated. As previously described, intra-articular injection
of MIA into the knee joint of rats resulted in significant decreases
in weight bearing on the ipsilateral hind limb and mechanical
withdrawal thresholds of the ipsilateral hindpaw, compared to
saline-treated rats (Figure SF1 in File S1). In line with our previous
study [19], pain behaviour was significantly different to saline
controls by day 7 post MIA injection, and was maintained for at
least 28 days (Figure SF1 in File S1). Repeated systemic dosing
with JWH133 significantly attenuated the development of pain
behaviour (significant change in weight bearing from day 14 and
mechanical withdrawal thresholds from day 10) in MIA-treated
rats (Fig 1A). OA is associated with dynamic changes in levels of
circulating cytokines (see references in [34,35]), in the MIA model
there was a trend towards increased serum levels of pro-
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inflammatory IL-1b and TNFa in MIA-treated rats, compared to
saline-treated rats (Fig 1B). Levels of the anti-inflammatory
cytokine IL-10 were significantly decreased in MIA-treated rats,
compared to saline-treated rats (Fig 1B). Systemic JWH133
prevented the MIA-induced alterations in serum levels of cytokines
(Fig 1B).
Given that the spinal cord plays a pivotal role in the integration
and modulation of central sensitization, the potential contribution
of a spinal site of action to the effects of the CB2 receptor ligand
was investigated. Spinal administration of JWH133 in MIA-
treated rats with established pain behaviour, significantly de-
creased innocuous and noxious mechanically (15 and 26 g) evoked
firing of wide dynamic range (WDR) neurones, compared to the
effect of vehicle in MIA-treated rats (Fig 1C, D). The inhibitory
effects of JWH133 on evoked neuronal responses were dose-
related and blocked by the CB2 receptor antagonist SR144528
(Fig 1C). Interestingly the inhibitory effects of JWH133 on evoked
responses of spinal neurones were only observed in the model of
OA pain and not control rats (Fig 1C), indicating a novel effect of
this intervention in the model of OA.
Increased expression of spinal CB2 receptors in the MIA
model of OA pain
To investigate why there was a novel inhibitory effect of the CB2
receptor agonist in MIA-treated rats, the expression and localisa-
tion of CB2 receptors in the spinal cord was quantified in MIA-
treated rats. At day 28 post model induction, CB2 mRNA levels
were significantly increased in the ipsilateral spinal cord of MIA-
treated rats, compared to the contralateral spinal cord, but there
were no differences between MIA- and saline-treated rats (Fig 2A).
Levels of CB2 mRNA in the ipsilateral and contralateral spinal
cord of saline-treated rats were comparable. Immunofluorescence
studies localised CB2 receptor protein in the dorsal horn of the
spinal cord in the rat (Figure SF2A in File S1). There was a
significant increase in the number of CB2 expressing Iba-1 positive
Figure 1. (A) Repeated systemic administration of the CB2 receptor agonist JWH-133 (1 mg/kg; day 1–28) attenuated MIA-induced changes in
weight bearing (p,0.001 area under the curve analysis of MIA + Vehicle vs. MIA + JWH133) and mechanical withdrawal thresholds (p,0.001 area
under the curve analysis of MIA + Vehicle vs. MIA + JWH133) of the ipsilateral hindpaw, n = 8 rats per group). (B) Effects of repeated systemic
administration of the CB2 receptor agonist JWH-133 (1 mg/kg; day 1–28) on MIA-induced changes in serum levels of IL-1b, TNF-a and IL-10. Analysis
of IL-1b and TNF-a used a one sample t-test using detection limit of kit as hypothetical value as there was no variation in saline + vehicle group and
MIA + JWH133 group, for IL-10 data a one-way ANOVA and a Bonferroni post-hoc test was used, **p,0.01, ***p,0.001 (n = 4–6 rat serum samples
per group). (C–D) Effects of spinal JWH-133 on noxious (15 g and 26 g) mechanically evoked responses of WDR neurones in MIA-treated rats (n = 6
neurones in 6 rats) and saline-treated rats (n = 6 neurones). Spinal administration of vehicle did not alter evoked responses of neurons in MIA-treated
rats (n = 7 neurones in 7 rats). Effects of JWH-133 (156 ng/50 mL) were abolished in the presence of SR144528 (n = 6 neurones in 6 rats; 0.001 mg/50 ml)
as indicated by open circle data point on bottom two panels. Data are expressed as mean maximal inhibition (% of pre-drug response) 6 SEM.
Statistical analyses were performed using a Kruskal Wallis test or Mann Whitney test as appropriate (*p,0.05, **p,0.01 for MIA-JWH133 versus MIA-
Vehicle and + p,0.05 for MIA-JWH133 versus MIA-JWH+SR144528). (D) Representative trace of innocuous (10 g) and noxious (15–60 g) mechanically
evoked responses of a single dorsal horn neurone before and 30 minutes following spinal administration of JWH-133 (156 ng/50 mL) in MIA-treated
rats.
doi:10.1371/journal.pone.0080440.g001
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activated (as indicated by an amoeboid morphology [19])
microglia (Fig 2B, C) and Neu-N positive neurones (Fig 2B, C),
in MIA-treated rats, compared to the contralateral side, and
compared to saline-treated rats. The number of GFAP positive
cells (a marker of reactive gliosis) expressing CB2 receptor protein
was negligible, indicating little expression of CB2 receptor protein
by astrocytes in the spinal cord (data not shown). Validation
experiments with the CB2 receptor antibody using spinal cord
tissue from wildtype and CB2 receptor knockout mice were
undertaken (Figure SF2B, C and SF3 in File S1). The number of
CB2 positive Iba-1 positive microglia was lower in spinal cord from
CB2 knockout mice (361 Iba-1 positive microglia per section),
compared to wild type spinal cord (1563 Iba-1/CB2 positive
microglia per section) (5–8 sections per mouse, 3 mice per
genotype. Similarly, numbers of CB2 positive Neu-N positive cells
were lower in spinal cord from CB2 knockout mice (161 CB2
positive neurons per section), compared to wild type spinal cord
(761 CB2 positive neurons per section).
Since some residual CB2 receptor immunofluorescence was
apparent in the knockout tissue, a fluorescently labelled CB2
receptor antagonist NIR660-Mbc94 (Figure SF4-SF6 in File S1),
was used to validate the observation that CB2 receptor expression is
increased in the spinal cord in the model of OA pain. In order to
establish that this fluorescent probe bound to CB2 receptors, a
combination of CB2 selective ligand competition binding and
confocal microscopy experiments were conducted (Figure SF7 in
File S1). We report competition specific binding of NIR660-Mbc94
to CB2 receptors, and that the cellular binding pattern of NIR660-
Mbc94 (intense staining of the surface of cells) is consistent with a
plasma membrane localisation. CB2-selective NIR660-Mbc94
binding in the ipsilateral lumbar spinal cord of MIA-treated rats
was a significantly increased compared to binding in the contralat-
eral spinal cord of MIA-treated rats, and compared to the ipsilateral
spinal cord of saline-treated rats (Fig 2D). These data support our
immunohistochemical evidence that CB2 receptors are up-regulated
in the spinal cord in this model of OA pain.
Figure 2. (A) CB2 mRNA expression in the ipsilateral and contralateral lumbar spinal cord of MIA- and saline-treated rats. Data are normalised to
levels of b-actin (mean6 SEM, n = 4–5 per group), region/treatment comparison was performed with a one way ANOVA and Neuman-Keuls post-hoc
test, ***p,0.001. (B) Representative images of CB2 receptor immunofluorescence localised with markers for neurones (Neu-N) and microglia (Iba-1) in
the dorsal horn of spinal cord (scale bar = 10 mm). (C) Quantification of the number of Iba-1 positive and Neu-N positive cells in the dorsal horn of the
spinal cord which co-express CB2 receptor immunofluorescence. Data are expressed as mean 6 SEM, statistical analysis were performed using a one
way ANOVA followed by Bonferroni post-hoc (n = 5–6 sections per rat, 5–6 rats per group),*p,0.05, **p,0.01. (D) Quantification of CB2 probe (AU) in
ipsilateral and contralateral dorsal horn quadrants in sections from MIA-treated (n = 5) and saline-treated (n = 4) rats (mean + SEM, 5–6 spinal cord
sections per rat),*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0080440.g002
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Activation of CB2 receptors attenuates spinal
mechanisms of central sensitization in the model of OA
pain
The next series of experiments investigated why CB2 receptor
activation inhibits spinal nociceptive processing in the model of
OA pain, but not the physiological processing of noxious inputs in
control rats. It is established that reactive gliosis plays a crucial role
in the maintenance of central sensitization in chronic pain states
[27], and activation of metalloprotease-2 and metalloprotease-9
(MMP-2 and MMP-9) has recently been implicated in the
activation of astrocytes [36]. We postulated that the up-regulation
of CB2 receptors in the spinal cord attenuates MMP-2 and MMP-
9 activity and concomitantly the activation of astrocytes in the
spinal cord, which puts a brake on the processes underpinning
central sensitization. Consistent with our previous work [19],
GFAP immunofluorescence, a marker of reactive gliosis, was
significantly increased in the ipsilateral spinal cord of MIA-treated
rats, compared to saline-treated rats (Fig 3A, B). In addition, we
demonstrate for the first time that the pro- and active forms of
MMP-2 are significantly elevated in the spinal cord of MIA-
treated rats, compared to saline-treated rats (Fig 3C, D, Figure
SF8A, B in File S1). A single band corresponding to MMP-9
activity was detected in the spinal cords of MIA-treated rats,
(Fig 3C). Systemic administration of the CB2 receptor agonist
JWH133 prevented the MIA-induced increase in spinal GFAP
immunofluorescence (Fig 3A, B), and MMP-2 activity and MMP-9
activity in the spinal cord (Fig 3C, D). These data strongly support
the hypothesis that activation of CB2 receptors inhibits essential
cellular mechanisms associated with the manifestation of central
sensitization in this model of OA pain.
Are there changes in CB2 mRNA in human spinal cord
associated with joint pathology
Given that our data suggest that CB2 receptors attenuate central
sensitization mechanisms and pain behaviour in the MIA model of
OA pain, the final experiments investigated potential associations
between knee joint damage (macroscopic chondropathy score) and
CB2 receptor gene expression in human lumbar spinal cord
(n = 11 cases). In addition, associations between spinal expression
of GFAP, TRPV1 and COX2 mRNA and macroscopic chondro-
pathy score were also determined in these cases. Macroscopic
chondropathy score were within the range of: 83–523, unfortu-
nately pain scores for these cases were not available. There was a
significant negative correlation between joint chondropathy score
and spinal CB2 mRNA expression (normalised to b-actin) in these
samples (Fig 4A). There was no significant correlation between
CB2 mRNA expression and age (Spearmans r: 0.23 p= 0.50).
Spinal GFAP mRNA expression was positively correlated with
chondropathy score (Fig 4B) and with age (Pearsons r value of 0.62
p= 0.04). There was no correlation between chondropathy score
and spinal CB1 mRNA expression (Spearmans r: 0.38 p= 0.12),
nor between chondropathy score and spinal COX-2 mRNA
expression (Spearmans r: 0.20 p= 0.28), nor between chondro-
pathy score and spinal TRPV1 expression (Pearsons r value of
0.42 p= 0.1831).
Discussion
We have shown that the CB2 receptor agonist JWH133, which
lacks centrally mediated side-effects (catalepsy and motor distur-
bances) seen with CB1 receptor agonists such as D
9-THC [37],
attenuated pain behaviour and spinal neuronal responses in a
model of OA pain. The up-regulation of the inhibitory CB2
receptor system in the spinal cord in the model of OA pain, and its
ability to modulate the cellular mechanisms underpinning the
manifestation of central sensitization, suggest novel therapeutic
potential of this target.
The experimental model of OA-like pain used in the present
study produces clinically relevant joint pathology, distal allodynia
and, by day 28, spinal correlates of central sensitization [17], thus
mimicking clinical features of pain reported in OA patients [2].
Here we demonstrate that systemic administration of the CB2
receptor agonist (JWH133) attenuated the development and
maintenance of pain OA behaviour. It is noteworthy that unlike
CB1 receptor agonists [38], we did not observe any evidence of
tolerance to the effects of repeated systemic administration of the
CB2 receptor agonist over the course of the study. Activation of
CB2 receptors has well described anti-inflammatory effects,
attenuating pro-inflammatory signalling pathways mediated by
interferon gamma [28,39] and interleukin 1 beta [28] and CB2
receptor activation potentiates anti-inflammatory signalling medi-
ated by interleukin-10 in other models of chronic pain [28].
Clinical OA is associated with changes in levels of cytokines
[34,35,40] which can modulate pain through a variety of
mechanisms including peripheral and spinal sensitization
[28,41,42]. Here we demonstrate that circulating levels of pro-
and anti-inflammatory cytokines are altered in the MIA model and
that treatment with the CB2 receptor agonist prevented these
changes in circulating cytokines.
The demonstration herein that a CB2 receptor agonist
(JWH133) can attenuate pain behaviour and evoked spinal
neuronal responses in MIA-treated rats which had established
chronic pain behaviour, but not in control rats, is consistent with
previous reports of a functional role of spinal CB2 receptors in
modulating neuropathic pain responses [25,28,39,43] and the
observation that over-expression of CB2 receptors is associated
with a reduced pain phenotype in MIA-treated mice [24]. The
inhibitory effects of the CB2 receptor agonist in MIA-treated rats
on spinal neuronal responses were blocked by the selective CB2
receptor antagonist SR144528. We report subtle, but significant,
changes in the spinal CB2 mRNA in this model of OA pain. Levels
of CB2 mRNA were significantly increased in the ipsilateral spinal
cord of MIA-treated rats, compared to the contralateral side. The
recent report that ipsilateral spinal CB2 mRNA levels are
decreased at later time-points in the mouse MIA model indicates
that there are temporal changes in CB2 mRNA expression as OA
progresses [24]. We report the first evidence for the expression of
CB2 mRNA in the human spinal cord, and demonstrate a negative
correlation with joint chondropathy. A positive correlation
between the extent of chondropathy and pain has previously been
reported [44], supporting the clinical utility of this approach.
Chondropathy scores from patients in the current study (median
per knee 112.4 (IQR 80 to 187)) were comparable to those
reported in post-mortem cases (median 44 (IQR 18 to 87), and
lower than those in most people presenting for joint replacement
surgery (median 257 (IQR 228 to 283)) [32]. The negative
association between CB2 mRNA levels and chondropathy in
human spinal cord may reflect events associated with later
stages of joint pathology, which is consistent with the reported
observations at later stages of the MIA model [24]. Collectively
clinical and pre-clinical evidence suggests that increased spinal
CB2 mRNA expression early during the development of OA, as
seen in the present study, may act to counter nociceptive
signalling, whilst later reductions in spinal CB2 mRNA expression
[24] may represent a failure of such homeostatic mechanisms and
contribute to the progression of central sensitization and the
manifestation of chronic OA pain. Changes in spinal CB2 receptor
mRNA expression in OA suggest an important role of this target
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Figure 3. (A) Representative images of GFAP immunofluorescence, a marker of reactive gliosis, in the ipsilateral and contralateral dorsal horn of the
spinal cord. Images are from rats that received intra-articular injection of saline or MIA, and treatment with vehicle or the CB2 receptor agonist
JWH133 (1 mg/kg, days 1–28) (scale bar = 5 mm). (B) Quantification of ipsilateral GFAP immunofluorescence expressed as a % of the
immunofluorescence for the contralateral spinal cord for the three treatment groups (n = 6–7 sections per rat, n = 4 rats per treatment). Systemic
administration of JWH-133 significantly attenuated increases in GFAP immunofluorescence, compared to the effects of vehicle, statistical analysis was
conducted via a one-Way ANOVA with a Bonferroni post-hoc test,*p,0.05. (C) Example gel zymography of MMP-9 and MMP-2 activity in the spinal
cord from the various treatment conditions, as well as positive controls for purified MMP 2 and MMP 9. (D) Quantification of MMP-9 and pro and
active MMP-2 activity in the ipsilateral spinal cord in MIA-treated rats and saline-treated rats. Systemic administration of JWH-133 significantly
attenuated increases in MMP-9, MMP-2 and active MMP-2 activity in the spinal cord in MIA-treated rats, compared to the effects of vehicle. Data are
expressed as mean densitometry 6 SEM (n = 4 rats per group), statistical analysis one-way ANOVA and Bonferroni post-hoc test,**p,0.01,
***p,0.001 vs. saline/Vehicle; #p,0.05, ###p,0.001 vs. MIA/Vehicle.
doi:10.1371/journal.pone.0080440.g003
Figure 4. (A) CB2 receptor mRNA expression in the lumbar spinal cord was negatively correlated with macroscopic knee chondropathy scores. (B)
GFAP mRNA expression in the lumbar spinal cord was positively correlated with macroscopic knee chondropathy scores. Data are expressed as mean
(normalised to beta actin) 6 SEM, statistical analysis (n = 11 separate spinal cord cases). Data were analysed with either a Pearson correlation or
Spearman correlation depending on whether data passed normality testing.
doi:10.1371/journal.pone.0080440.g004
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in regulating nociceptive processing in this disease, and our
preclinical data indicate the therapeutic potential of CB2 agonists
in relieving OA pain, at least at early stages of the disease. We also
report a positive correlation of spinal GFAP mRNA expression
and chondropathy score. As discussed earlier, astrocyte reactivity
in the spinal cord is considered to be an important feature in the
transition from acute to chronic pain mechanisms [9,10]. The
positive correlation between spinal GFAP expression and age may
indicate, however, that changes in GFAP expression are driven by
age, rather than joint chondropathy.
Immunohistochemistry studies presented herein provide new
evidence for a significant increase in CB2 receptor protein
expression in the ipsilateral spinal cord of MIA-treated rats.
However control studies revealed that 10–20% of spinal CB2
positive cells present in the wild-type mouse were still present
in spinal cord from CB2 knockout mouse, which suggests a lack
of selectivity of the antibody or the incomplete knockout out of
the CB2 receptor. Fluorescence labelling of the CB2 receptor
with the novel probe NIR660-Mbc94 consolidated evidence for
a significant increase in CB2 receptor protein expression in the
ipsilateral spinal cord in this model of OA pain. NIR660-
Mbc94 exhibited a moderate level of non-specific binding, as
seen with other cannabinoid probes [45,46]. Nevertheless, with
appropriate experimental controls, this probe produces robust
and reproducible binding in spinal cord sections and is an
important new tool for the study of CB2 receptor protein in
tissue ex vivo.
To further understand the mechanism(s) by which local
activation of CB2 receptors attenuated nociceptive responses of
spinal neurones in MIA-treated rats which had established chronic
pain behaviour, but not in control rats, the cellular localisation of
CB2 receptor protein was determined. The number of activated
Iba-1 positive microglia and neurones (Neu-N) in the ipsilateral
dorsal horn of the spinal cord which co-labelled the CB2 receptor
antibody was significantly increased in MIA-treated rats, com-
pared to the contralateral spinal cord and saline-treated rats. The
contribution of glial cells to central sensitization is well known (see
earlier), and the expression of CB2 receptors on (morphologically
defined as activated) microglia is consistent with that reported for
neuropathic pain models (see introduction). The expression of CB2
receptor protein by neurones (Neu-N) is in keeping with an earlier
report [39] and the description of functional synaptic CB2
receptors in the CNS [47]. Our study demonstrates changes in
spinal CB2 receptor expression by at least 2 different cell types,
which provides multiple mechanisms by which agonists acting at
this receptor can differentially regulate nociceptive processing in
OA rats, compared to control rats. The inhibitory effects of the
CB2 receptor agonist on pain behaviour were associated with a
significant reduction in GFAP immunofluorescence in the spinal
cord, indicative of a decrease in the level of reactive gliosis, which
is associated with the maintenance of central sensitization in
chronic pain states [27]. Furthermore, the ability of this treatment
to attenuate the activation of spinal MMP-2 and MMP-9, which
has been implicated in the activation of astrocytes [36], provides a
novel mechanism by which activation of CB2 receptors dampens
down central sensitization mechanisms, resulting in an attenuation
of pain behaviour.
In conclusion, activation of CB2 receptors attenuated the
development and maintenance of OA-induced pain behaviour.
We provide electrophysiological evidence that acute activation of
spinal CB2 receptors selectively attenuates spinal neuronal
processing of noxious inputs in the established OA pain model.
Mechanistic studies demonstrate the up-regulation of CB2
receptors in the spinal cord in this model of OA pain and suggest
that CB2 receptor-mediated modulation of spinal neuro-immune
responses contributes to the inhibitory effects of this target on OA
pain responses. Our clinical and pre-clinical data support the
further investigation of the potential of CB2 receptor agonists for
the treatment of pain associated with OA, in particular at earlier
stages of the disease.
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